Cited by 485Antifungal resistance and susceptibilityCOVID-19 Clinical Research StudiesInfectious Diseases and Mycology

Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India

Open access
Patel, Atul, Agarwal, Ritesh, Rudramurthy, Shivaprakash M., Shevkani, Manoj, Xess, Immaculata, Sharma, Ratna, Savio, Jayanthi, Sethuraman, Nandini +12 more·2021·Emerging Infectious Diseases

Abstract

econdary infections are known to complicate the clinical course of coronavirus disease .Bacterial infections are the most common secondary infections, but increasing reports of systemic fungal infections are causing concern.In the early part of the COVID-19 pandemic, <1% of secondary infections reported in COVID-19 patients were fungal (1,2).Preexisting conditions, indiscriminate use of antimicrobial and glucocorticoid drugs, and lapses in infection control practices are putative factors contributing to the emergence of systemic fungal infections in severe COVID-19 cases (3).After incidence of candidemia and invasive aspergillosis in COVID-19 patients increased (4,5), awareness of possible fungal co-infections increased among clinicians and microbiologists.One study reported invasive fungal infections in ≈6% of hospitalized COVID-19 patients (6).Occasional reports of COVID-19-associated mucormycosis (CAM) from various centers (7,8) and a series of 18 cases from a city in South India increased our concerns about CAM (9).India has a high burden of mucormycosis among patients with uncontrolled diabetes mellitus, and many severe COVID-19 patients have diabetes (8,10).India also is one of the countries worst affected by the COVID-19 pandemic.Thus, we would expect India to have many CAM cases.We conducted a nationwide multicenter study to evaluate the epidemiology and outcomes of CAM and compare the results with cases of mucormycosis unrelated to COVID-19 (non-CAM).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3201/eid2709.210934

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In India, a steep increase of mucormycosis cases was observed during the COVID-19 pandemic, driven by specific immunological mechanisms, overuse of systemic corticosteroids, and an increase in the population with undiagnosed or uncontrolled diabetes.

    “In India, a steep increase of mucormycosis cases was observed during the COVID-19 pandemic [88,89], driven by specific immunological mechanisms that predispose COVID-19 patients to mucormycosis [87], as well as overuse of systemic corticosteroids and an increase in the population with undiagnosed or uncontrolled diabetes [88].”

    From Race and ethnicity: Risk factors for fungal infections? (2023) · cites this paper as [89]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 30 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Patel, A., Agarwal, R., Rudramurthy, S. M., Shevkani, M., Xess, I., Sharma, R., Savio, J., Sethuraman, N., Madan, S., Shastri, P., Thangaraju, D., Marak, R., Tadepalli, K., Savaj, P., Sunavala, A., Gupta, N., Singhal, T., Muthu, V., Chakrabarti, A., & Network3, M.
Affiliations
  • Sterling Hospitals (IN)
  • Medanta The Medicity (IN)
Corresponding author
Chakrabarti, Arunaloke
Venue
Emerging Infectious Diseases
Published
2021-09
Volume
27
Issue
9
Pages
2349-2359
ISSN
  • 1080-6040 (ISSN-L)
  • 1080-6059
OpenAlex
W3164172839
Cited by
479
References
30
Citations by year
2026: 26 · 2025: 35 · 2024: 60 · 2023: 114 · 2022: 163 · 2021: 81
FWCI
33.10
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Emerging infectious diseases (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Veterinary › Small Animals › Infectious Diseases and Mycology
Keywords
COVID-19-associated mucormycosis, mucormycosis, SARS-CoV-2, secondary fungal infection, invasive fungal infections, clinical outcomes, diabetes mellitus, glucocorticoid use
MeSH terms
COVID-19, SARS-CoV-2, Antifungal Agents, Humans, India, Mucormycosis, Retrospective Studies, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review